Kenvue stock gains as Kimberly-Clark moves to secure EU approval for $40 billion deal
Published on 09/15/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kenvue stock closed at USD 24.80 on the New York Stock Exchange on September 14, 2026, marking a 2.0 percent gain over the prior session and reflecting renewed confidence as Kimberly-Clark’s planned USD 40 billion acquisition advances through regulatory review.
Regulatory progress drives Kenvue move
According to Reuters on September 14, 2026, Kimberly-Clark is preparing concessions, including potential asset sales, to address European Commission antitrust concerns about its bid for Kenvue, the Tylenol maker, in order to secure approval for the roughly USD 40 billion transaction in phase one of the EU review.
As Seeking Alpha reported on September 14, 2026, shares of Kenvue rose about 2 percent in response to the news that Kimberly-Clark would make adjustments to alleviate EU antitrust apprehensions, while Kimberly-Clark’s own stock gained roughly 2.5 percent on the same day.
Traders cited by Seeking Alpha on September 15, 2026 expect the European Commission to grant phase-one approval for the Kenvue deal with remedies, a scenario that would remove one of the biggest regulatory uncertainties overhanging Kenvue stock.
Latest earnings show modest growth and strong dividend
In the second quarter of 2026, Kenvue reported revenue of USD 3.95 billion, an increase of 3 percent year over year, while earnings per share reached USD 0.24, which represents a 9 percent rise compared with the same period a year earlier, according to The Motley Fool on September 14, 2026.
Based on Kenvue’s current share price, its dividend yield stands at 4.68 percent, more than four times the average S&P 500 dividend yield and nearly twice the yield of the average Dividend King, as highlighted by The Motley Fool on September 14, 2026.
For income-focused investors, the combination of mid-single-digit revenue growth, a 9 percent year-over-year increase in EPS in the second quarter of 2026, and a dividend yield around 4.68 percent makes Kenvue stock an attractive cash-return vehicle, but the pending takeover by Kimberly-Clark could alter the company’s standalone dividend policy once the transaction closes.
Deal structure and regional asset sale plans
The potential reshaping of Kenvue’s portfolio is already visible at the regional level. As Metissue reported on September 15, 2026, Sorbent Paper Company has signed an agreement with a Kenvue Singapore subsidiary to acquire its Stayfree and Carefree feminine care business in Australia and New Zealand, with the New Zealand business to be managed by Sorbent’s affiliate Cottonsoft after completion.
According to Metissue on September 15, 2026, that regional transaction is subject to regulatory approval in Australia and New Zealand, customary closing conditions, and the completion of the broader Kimberly-Clark and Kenvue deal, underscoring how local portfolio moves are being sequenced behind the global takeover.
While financial terms of the Sorbent deal have not been disclosed, the planned sale illustrates how Kimberly-Clark and Kenvue could use targeted disposals to satisfy competition authorities and streamline the combined group’s product footprint in specific markets.
Analyst and market perspectives on the takeover
Commentary from valuation-focused investors suggests that the acquisition comes at a time when Kimberly-Clark is seeking to expand more deeply into consumer health. On September 14, 2026, GuruFocus noted that the proposed Kenvue acquisition is facing regulatory scrutiny in Europe and China, with the EU’s decision deadline set for September 29 and China’s antitrust authority conducting a thorough review of the deal.
According to GuruFocus on September 14, 2026, news of Kimberly-Clark’s adjustments to address EU antitrust concerns led to a 2 percent gain for Kenvue and a 2.5 percent rise in Kimberly-Clark, signaling that investors welcome signs of proactive engagement with regulators.
The same article from GuruFocus on September 14, 2026 highlighted that failure to resolve antitrust concerns could delay or reshape the transaction, a risk that Kenvue shareholders must weigh against the takeover premium and potential integration benefits.
Key fundamental comparison and investor takeaway
The second-quarter 2026 figures demonstrate that Kenvue is growing steadily: revenue of USD 3.95 billion was up 3 percent year over year, while EPS of USD 0.24 increased 9 percent over the same period, which shows that earnings are expanding three times faster than sales, pointing to margin improvement or cost efficiencies in the business, according to The Motley Fool on September 14, 2026.
For shareholders, the interplay between these improving fundamentals and the high dividend yield means Kenvue stock delivers a blend of income and moderate growth, but the pending acquisition introduces event risk, including possible changes to payout policy once Kimberly-Clark assumes control.
The regulatory calendar is therefore crucial: the European Commission’s phase-one review, expected to conclude by September 29, 2026, will give Kenvue investors clearer visibility on whether the deal proceeds quickly with remedies or enters a more protracted investigation phase, as outlined by Reuters on September 14, 2026.
Stock price level and market data
Kenvue stock (ISIN US49177J1025, NYSE: KVUE) ended the September 14, 2026 session at USD 24.80 on the New York Stock Exchange after opening near USD 24.20, which represents a 2.0 percent gain versus the prior close, per recent exchange data.
On September 14, 2026, the shares traded in an intraday range between USD 24.10 and USD 25.05, with volume noticeably above their recent average, indicating that news flow around the EUR regulatory process and expected remedies is drawing additional trading interest.
Kenvue stock - key data
- Company: Kenvue Inc.
- ISIN: US49177J1025
- Ticker: KVUE
- Trading venue: NYSE
- Price (as of September 14, 2026, 16:00): 24.80 USD
- Sector / Industry: Consumer health / Household and personal products
- Index membership: S&P 500
